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Abstract
Background: Fluoropyrimidines form the chemotherapy 
backbone of advanced and metastatic colorectal cancer 
(CRC). These drugs are frequently associated with toxicity 
events that result in dose adjustments and even suspen-
sion of the treatment. The thymidylate synthase (TYMS) 
gene is a potential marker of response and toxicity to 
fluoropyirimidines as this enzyme is the molecular target 
of these drugs. Our aim was to assess the association 
between variants of TYMS with response and toxicity to 
fluoropyrimidines in patients with CRC in independent 
retrospective and prospective studies.
Methods: Variants namely rs45445694, rs183205964, 
rs2853542 and rs151264360 of TYMS were genotyped in 105 
CRC patients and were evaluated to define their associa-
tion with clinical response and toxicity to fluoropyrimi-
dines. Additionally, the relationship between genotypes 
and tumor gene expression was analyzed by quantitative 
polymerase chain reaction.
Results: The 2R/2R (rs45445694) was associated with clin-
ical response (p = 0.05, odds ratio (OR) = 3.45) and severe 
toxicity (p = 0.0014, OR = 5.21, from pooled data). Expres-
sion analysis in tumor tissues suggested a correlation 
between the 2R/2R genotype and low TYMS expression.
Conclusions: The allele 2R (rs45445694) predicts severe 
toxicity and objective response in advanced CRC patients. 
In addition, the alleles G(rs2853542) and 6bp-(rs151264360) 
are independent predictors of response failure to chemo-
therapy. This is the first study made on a Latin American 
population that points out TYMS gene variants have pre-
dictive values for response and toxicity in patients with 
CRC treated with fluoropyrimidine-based chemotherapy.
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Introduction
Tumors of the large bowel are a leading cause of mor-
bidity and mortality due to cancer in Mexico [1]. 5-Fluo-
rouracil (5-FU) and capecitabine are fluoropyrimidines 
constituting the corner stone for chemotherapy against 
gastrointestinal tumors. Its application in the treatment 
of metastatic colorectal cancer has represented a sig-
nificant development in terms of overall survival, com-
pared to the support therapy for patients [2]. Despite 
this, there is not one predictive biomarker of response 
for the current first-line scheme based on fluoropyri-
midines that can be applied to patients with advanced 
colorectal cancer (CRC) and the search for useful pre-
dictive biomarkers of response to fluoropyrimidines to 
guide effective therapeutic decisions is still in progress 
[3, 4]. In the context of personalized medicine, these 
types of biomarkers are fundamental to ensure the 
maximum possible benefit for a specific treatment and 
to extend the spectrum of potential diseases that could 
benefit from a specific therapy.
Another key consideration of biomarkers for cancer 
chemotherapy is their prediction proficiency for adverse 
events. In the case of fluoropyrimidines, serious toxicity is 
observed in up to 14% of the cases with oral treatment and 
up to 42% with systemic therapy [5]. Concerning the pre-
dictive markers of toxicity to fluoropyrimidines, variants 
in the gene dihydropyrimidine dehydrogenase responsi-
ble for the limiting step in the metabolism of 5-FU were 
associated with severe toxic events, resulting in even fatal 
outcomes. However, the low allelic frequency of these 
variants in the general population, coupled with their low 
sensitivity to predict toxic events in the clinic, points out 
to the presence of other possible biomarkers associated 
with fluoropyrimidines toxicity [6, 7].
The TYMS gene codifies for the thymidylate syn-
thase enzyme involved in the de novo synthesis of 
deoxythymidine monophosphate. As this enzyme is the 
pharmacological target for the fluoropyrimidines, TYMS 
gene variations are attractive candidates for pharma-
cogenetic studies. However, the coding region of the 
TYMS gene is highly stable, so only few variants with 
some functional effect were reported, even in tumor 
tissues; so attention has turned to the variants present 
in the noncoding regions of the gene [8]. The potential 
use of variants in the 5′UTR (untranslated region) and 
3′UTR flanks has been investigated in several studies of 
the TYMS gene as genetic biomarkers to predict clini-
cal response in gastrointestinal tumors. However, the 
results are conflicting and there is no consensus on the 
clinical value of these variants [9–11]. For instance, while 
some studies report association between a favorable 
clinical response and variants at the 5′UTR and 3′UTR 
regulatory regions of the TYMS gene, other reports have 
failed to replicate such results [12–16]. None of these 
studies was performed on the Latin-American popula-
tions and studies in this group may contribute to the 
understanding of the biological significance of TYMS 
variants and their pharmacological relevance for CRC 
patients undergoing chemotherapy.
The present study deals with the identification of 
germ-line variants in noncoding regions of the TYMS 
gene in Mexican patients with CRC from two independ-
ent analyses: retrospective and prospective studies, aimed 
at evaluating the predictive power of these variants in 
the development of serious toxicity events and lack of 
response to first-line chemotherapeutic scheme based on 
fluoropyrimidines for advanced colorectal tumors. Addi-
tionally, we analyzed the expression of the TYMS gene in 
fresh samples of tumor and nontumor tissues of colorectal 
origin and their association with these variants.
Materials and methods
Study design and patients
We reviewed clinical records and tested samples of 99 patients with 
advanced CRC (stages III–IV according to the TNM classification) 
receiving 5-FU or capecitabine in the High Specialties Unit N°25 of 
the Mexican Institute for Social Security (IMSS) during 2010–2012 
for retrospective analyses. These study subjects participated in the 
genome wide association study entitled “Genetic study of Common 
Hereditary Bowel Cancers in Hispania and the Americas” (FP7 Pro-
gram). In addition, 68 patients with similar clinic characteristics and 
chemotherapeutic regime were recruited for a prospective study to 
analyze treatment toxicity and clinical response during 2013–2015 in 
the same hospital. Clinical protocols were approved by the respective 
Ethics Committees of the following participating institutions: Uni-
versity Hospital of Universidad Autonoma de Nuevo Leon (approval 
code BI13-002), High Specialties Unit N°25, IMSS and West National 
Medical Center, IMSS (approval code R-2015-785-024). All patients 
signed an informed consent for their connection with the described 
studies. Categorization of objective clinical response was performed 
following the Guide to Response Evaluation Criteria in Solid Tumors 
(RECIST v1.1, 2009) and adverse events were evaluated by the Guide 
to Common Terminology Criteria for Adverse Events (CTCAE v4.03, 
2010). Patients for whom they could not get complete clinical infor-
mation or whose biological samples did not have the necessary 
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quality for subsequent analysis were excluded. After examining the 
clinical data and genomic DNA quality, 105 patients were selected 
for these pharmacogenetic studies (42 and 63 from the two recruiting 
campaigns).
Chemotherapy
Patients received the FOLFOX scheme consisting of IV infusion of 
400 mg/m2 leucovorin and 100 mg/m2 oxaliplatin in 2 h and a sub-
sequent bolus of 400 mg/m2 5-FU, followed by continuous infusion 
of 2400–3000 mg/m2 5-FU in 48 h every 2 weeks. As an alternative, 
some patients received the XELOX scheme consisting of IV infusion 
of 130  mg/m2 oxaliplatin every 3  weeks and 1000  mg capecitabine 
twice daily after meals.
The general physical condition of each patient was determined 
prior to the therapy according to the Eastern Cooperative Oncology 
Group (ECOG) scale and laboratory tests were performed to assess 
the baseline liver and kidney functions [17].
Genotyping
Genomic DNA was prepared from blood samples anticoagulated 
with etheylenediaminetetraacetic acid and stored at −20 °C until 
further processing. The DNA was isolated with the DNeasy Blood 
& Tissue Kit (QIAGEN, Hilden, Germany) following manufacturer 
instructions. The variable number of tandem repeats (VNTR) vari-
ants of the 5′UTR flank of TYMS (rs45445694), and their additional 
single nucleotide variant (SNV) G>C in the first repeat of the 2R 
allele (rs183205964, named 2RG or 2RC), the SNV G>C in the sec-
ond repeat of the 3R allele (rs2853542, named 3RG or 3RC), and the 
6 bp insertion in the second repeat of the 3R allele (rs538469385) 
(all located into the rs45445694 variant) were performed by poly-
merase chain reaction-restriction fragment length polymorphism 
using the primers 5012F19:5′-CGGGAAAAGGCGCGCGGAA-3′ and 
5147R18: 5′-GCAGCTCCGAGCCGGCCA-3 and HaeIII (New Eng-
land Biolabs, Ipswich, MA, USA). A 6-bp deletion variant at the 
3′UTR region of TYMS (rs151264360) was genotyped as previously 
reported [18]. Genotyping analyses were verified in duplicate for 
each specimen.
Quantitative TYMS expression analysis
All samples were blind evaluated by a pathologist to separate can-
cerous and normal fractions. Tumor and adjacent tissue samples 
were recovered from surgical specimens preserved in Tissue-Tek® 
Optimal Cutting Temperature (Sakura Finetek, Torrance, CA, USA) 
at −80 °C until processing. Some 10 μm slices cut at −20 °C were 
immediately processed for gDNA as previously reported [19] and 
for total RNA using the TRizol® reagent (Invitrogen, Carlsbad, CA, 
USA). The quality of the RNA was assessed by electrophoresis and 
spectrophotometry. The cDNA was synthesized with the Super-
Script® III First-Strand Synthesis kit (Invitrogen). The quantitative 
polymerase chain reaction study was performed using the SYBR® 
Green Master Mix (Bio-Rad. Hercules, CA, USA) in the CFX96™ 
Real Time System (Bio-Rad) using the primers T2211F: 5′-TAC-
CTGGGGCAGATCCAACACATC-3′ and T2211R: 5′-ACAGCAACTC-
CTCCAAAACACCC-3. The B2M gene expression was selected for 
normalization. Expression studies were performed in triplicate for 
both tested genes. Quantification of the relative expression of the 
TYMS gene was performed by the 2[-Delta Delta C(T)] method pre-
viously reported [20].
Statistical analysis
Deviations from the Hardy-Weinberg law were evaluated by the Pear-
son’s χ2-test. Univariate analyses were performed with one-tailed 
Fisher’s exact test and the Cochran-Armitage trend test. The likeli-
hood ratio test was employed to compare variant effects in different 
genetic models using the SNPstats program [21]. The selection of the 
best model was based on the joint analysis of the Akaike information 
criterion and the Bayesian information criterion. Multivariate logistic 
regression-based analysis was used for the adjustment of the genetic 
model selected with clinical or demographic covariates. Comparison 
of TYMS gene expression between tumor and adjacent-tissue sam-
ples was performed using the Mann-Whitney U test on linearized 
relative expression data. Two-tailed p < 0.05 values were considered 
significant in the different performed tests. All statistical tests were 
performed using the IBM SPSS Statistics software v22 (IBM Corp. 
Armonk, NY, USA).
Results
Association analysis for TYMS variants and 
toxicity in the retrospective study
A total of 42 patients from the retrospective study were 
included in these analysis. The variants analyzed in the 
present study are described in Table 1. Regarding the 
rs45445694 VNTR variant, only alleles with 2(2R) and 
3(3R) repeats were identified in the study sample. In 
addition, the G>C SNV inside the second repeat of the 3R 
variant (rs2853542) and the 6-bp deletion variant located 
in the 3′UTR region (rs151264360) were also identified. 
Variants ascertained in this study are shown in Figure 1. 
All other reported variants were not detected in the study 
subjects.
The patients were classified for toxicity according to 
CTCAE v4.03 and categorized into mild to moderate toxic-
ity (grades 0–2) and serious toxicity (grades 3–4) groups. 
Some 26% (11/42) of the patients experienced serious tox-
icity (Table 2). The main causes of toxicity were gastroin-
testinal toxicity (nausea, vomiting, diarrhoea), followed 
by neurological toxicity (dysesthesia and sensory neu-
ropathy). Some 7.1% (3/42) of the patients required dose 
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adjustment and treatment was suspended in 11.9% (5/42) 
of the patients because of severe toxicity. The most impor-
tant serious toxicities were diarrhoea and sensory neurop-
athy (14% and 7%, respectively). Death events related to 
the therapy were not reported.
The univariate analysis did not show associations 
among serious toxicity and age, sex, tumor stage or type 
of administered fluoropyrimidine (Supplemental Table 1). 
The likelihood ratio test determined that the 2R allele of 
the rs45445694 variant was significantly associated with 
an increased risk of serious global toxicity in a recessive 
genetic model (p = 0.023, odds ratio (OR) = 8.29, 95%CI 
1.25–54.71) (Table 3). The G>C inside the 3R variant (rs 
2853542) was not associated with serious toxicity to the 
fluoropyrimidines (p = 0.208, 6% vs. 25%).
Prospective analysis of association between 
variants and objective response
A total of 63 patients met the necessary conditions for their 
clinical and genetic evaluations in the prospective study. 
Patients were categorized into responder (partial or com-
plete response) or nonresponder (stable disease, disease 
progression, or death due to disease) groups, according to 
RECIST v1.1. The total objective response rate (ORR) was 
29%. Univariate analysis for therapeutic response against 
age (<57 vs. ≥57 years old), gender (male vs. female), and 
therapy (chemotherapy vs. chemotherapy + radiotherapy) 
did not show associations (Supplemental Table 2).
The allele discrimination analyses for this cohort identi-
fied the 2R (rs45445694), the G>C SNV inside the 3R allele 
(rs2853542, called 3RC allele) and the 6 bp deletion in the 
3′UTR region of TYMS (rs151264360) in frequencies of 0.48, 
0.46 and 0.33, respectively. Again, the G>C SNV inside the 
first repetition of the 2R allele (rs183205964) and the 6 bp 
insertion in the TYMS promoter (rs538469385) were not iden-
tified. All genotypes for the described TYMS variants were in 
Hardy-Weinberg equilibrium (Supplemental Table 3).
The association analysis for the VNTR (rs45445694) 
variant and tumor response rate showed that the 2R allele 
was associated with a positive patient response to chemo-
therapy in a recessive genetic model (p = 0.05; OR = 3.45, 
95% CI 1.00–11.99) (Table 4).
According to the VNTR and the SNV G>C (rs2853542) of 
the TYMS gene patients were categorized into genotypes of 
low (2R/2R, 2R/3RC, 3RC/3RC) and high (2R/3RG, 3RG/3RC, 
3RG/3RG) enzyme expression, based on functional analy-
ses previously reported [17]. This categorization showed a 
significant association between low gene expression vari-
ants and positive tumor response (p = 0.005, OR = 6.84, 
Figure 1: Topological description of the 5′UTR and 3′UTR variants in 
the TYMS gene.
Bold arrows indicate the direction of the coding sequence. Open 
squares show the variable number repeat variant (rs45445694) with 
either 2 or 3 repeat alleles. The G>C variant (rs2853542) is located 
inside the second repeat of the 3R allele. The dashed square shows 
the position of the del6bp variant (rs151264360) in the 3′UTR region 
of the gene.
Table 1: List of analyzed variants.
dbSNP IDa   Chromosome 
coordinatesb
  Nomenclaturec   Description
rs45445694   18:657646  LRG_783t1:c.-97_70CCGCGCCACTTGGCCTGCCTCC
GTCCCG [1–4, 7–9]
  VNTR of 28 nt in the 5′UTR region of the 
TYMS gene
rs183205964   18:657657  LRG_783t1:c.-86G>C   G>C transversion in the 12th nt of the first 
repeat of the 2R allele of the VNTR
rs2853542   18:657685  LRG_783t1:c.58G>C   G>C transversion in the 12th nt of the 
second repeat of the 3R allele of the VNTR
rs538469385   18:657697  LRG_783t1:c.-46_45insCCCCCG   Insertion of 6 nt in the second repeat of 
the 3R allele of the VNTR
rs151264360   18:673444  LRG_783t1:c.447_452delTTAAAG   Deletion of 6 nt in the 3′UTR region of the 
TYMS gene. Also named 1494del6
According with Human Genome Variation Society nomenclature recommendations. adbSNP build 147. b RefSeq entry: NC_000018.10 
GRCh38.p7. cRefSeq entry: NM_001071.
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95% CI 1.73–27.02). In contrast, the number of 3RG alleles 
in the genotype significantly correlated with therapeu-
tic failure (p = 0.0033) (Figure 2). The 6 bp-(rs151264360) 
variant at the 3′UTR was significantly associated in an 
additive genetic model with a positive response to chemo-
therapy (p = 0.02, OR = 4.81 for each deleted allele, 95% CI 
1.56–14.77) (Table 4).
Associations among toxicity and clinical, 
genetic and demographic factors in the 
 prospective analysis
Some 18 out of 63 of patients who reported toxicity devel-
oped serious adverse events due to chemotherapy, accord-
ing to the CTCAv4.01 Guide. Ten of these patients required 
dose adjustment and two required definitive therapy sus-
pension (Table 2). Gastrointestinal type toxicity was the 
most frequent, followed by neurological and hematologi-
cal toxicities (46%, 38% and 24%, respectively). No death 
events were reported in this prospective study.
None of the analyzed clinical and demographic 
factors (gender, age, type of treatment, drug, and ECOG 
performance status) showed association with serious tox-
icity to fluoropyrimidines in the univariate analysis (Sup-
plemental Table 4).
Regarding the rs45445694, rs2853542, and rs151264360 
TYMS variants, the 2R allele of rs45445694  was associ-
ated with severe toxicity to the fluoropyrimidine-based 
chemotherapy in a recessive genetic model in the multi-
variate analysis (p = 0.0024, OR = 4.11, 95% CI 1.19–14.25) 
(Table 3). The 3RG and 3RC alleles of rs2853542 were not 
associated with serious toxicity (27% vs. 22%, p = 0.566) 
suggesting that this variant lacks informational value for 
toxicity to fluoropyrimidines.
Combined multivariate analysis
The multivariate logistic regression analysis for combined 
toxicity data pooled from the retrospective study and 
the prospective study of CRC patients (n = 105, α = 0.05, 
Table 2: Distribution of toxicity events in the retrospective and prospective analysis of CRC patients.
Toxicity n (%)a
Retrospective (n = 42) Prospective (n = 63)
Total Grades 1–2 Grades 3–4 Total Grades 1–2 Grades 3–4
Gastrointestinal 20 (47.6) 13 (30.9) 7 (16.7) 29 (46.0) 20 (31.7) 9 (14.5)
Neurological 15 (35.7) 12 (28.6) 3 (7.1) 24 (38.1) 21 (33.3) 3 (4.8)
Hematological 4 (9.5) 3 (7.1) 1 (2.4) 15 (23.8) 12 (19.0) 3 (4.8)
Asthenia 10 (23.8) 9 (21.4) 1 (2.4) 16 (25.4) 14 (22.2) 2 (3.2)
Hand-foot syndrome 15 (35.7) 14 (33.3) 1 (2.4) 7 (11.1) 7 (11.1) 0 (0)
Other 9 (21.4) 5 (11.9) 4 (9.5) 3 (4.8) 2 (3.2) 1 (1.6)
All toxicities 42 (100) 31 (74.0) 11 (26.0) 63 (100) 45 (71.0) 18 (29.0)
Toxicities grading according with CTCAE v4.03. aPercentage with respect to the total population of patients in each study.
Table 3: Association of the VNTR with severe toxicity to fluoropyirimidine-based chemotherapy.
Genetic model Genotype n (%) OR (95% CI) p-Valuea
Toxicity (0–2) Toxicity (3–4)
Retrospective study of CRC patients (n = 42):
Recessive 3R/3R–2R/3R 29 (93.5) 7 (63.6) 1.00 0.023
2R/2R 2 (6.5) 4 (36.4) 8.29 (1.25–54.71)
Prospective study of CRC patients (n = 63):
Recessive 3R/3R–2R/3R 37 (86) 12 (60) 1.00 0.024
2R/2R 6 (14) 8 (40) 4.11 (1.19–14.25)
Pooled data (n = 105):
Recessive 3R/3R–2R/3R 66 (89.2) 19 (61.3) 1.00 0.0014
2R/2R 8 (10.8) 12 (38.7) 5.21 (1.86–14.59)
CI, confidence interval. Statistically significant associations are highlighted in bold. aLikelihood ratio test.
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statistical power = 80%), showed a significant association 
between the 2R/2R genotype adjusted by age and the risk 
of severe global toxicity to fluoropyrimidines (p = 0.0014, 
OR = 5.21, 95% CI 1.86–14.59) (Table 3). The post-hoc analy-
sis for prediction of chemotherapy toxicity establishes a 
recessive model for the association of the 2R allele with 
toxicity. This study ensures significant detection of the 
toxicity effect in the studied sample.
TYMS gene expression in colorectal tissues
Tumor and adjacent-tissue samples were available from 
16 patients for TYMS expression analysis. A trend to lower 
TYMS expression was observed in tumor tissues, although 
the comparison did not reach significance (Figure 3A). 
As expected, no associations between TYMS expression 
and rate of response to chemotherapy were found. The 
2R/2R genotype of the VNTR was significantly associated 
with a low relative expression of TYMS in tumor tissues 
(p < 0.05) (Figure 3B). Genotypic analyses in paired tumor 
and adjacent-tissue samples for the selected TYMS vari-
ants showed 100% correspondence, suggesting that none 
of the tumors presented loss of heterozygosity. No other 
association was found.
Table 4: Association of the VNTR and del6bp variants with the objective response of CRC patients to fluoropyrimidine-based chemotherapy 
in the prospective study.
Genetic model Genotype n (%) OR (95% CI) p-Valuea AICb BICc
Nonresponders Responders
VNTR (rs45445694)
Co-dominant 3R/3R 12 (26.7%) 4 (22.2%) 1.00 0.14 77.5 83.9
2R/3R 26 (57.8%) 7 (38.9%) 0.81 (0.20–3.30)
2R/2R 7 (15.6%) 7 (38.9%) 3.00 (0.64–14.02)
Dominant 3R/3R 12 (26.7%) 4 (22.2%) 1.00 0.71 79.2 83.5
2R/3R-2R/2R 33 (73.3%) 14 (77.8%) 1.27 (0.35–4.64)
Recessive 3R/3R-2R/3R 38 (84.4%) 11 (61.1%) 1.00 0.05 75.6 79.9
2R/2R 7 (15.6%) 7 (38.9%) 3.45 (1.00–11.99)
Over-dominant 3R/3R-2R/2R 19 (42.2%) 11 (61.1%) 1.00 0.17 77.5 81.8
2R/3R 26 (57.8%) 7 (38.9%) 0.47 (0.15–1.42)
Log-additive – – – 1.82 (0.80–4.15) 0.15 77.3 81.6
del6bp (rs151264360)
Co-dominant 6bp−/6bp− 6 (13.3%) 0 (0%) 1.00 0.007 71.3 77.8
6bp+/6bp− 24 (53.3%) 5 (27.8%) NA (0.00–NA)
6bp+/6bp+ 15 (33.3%) 13 (72.2%) NA (0.00–NA)
Dominant 6bp−/6bp− 6 (13.3%) 0 (0%) 1.00 0.038 75.1 79.4
6bp+/6bp− 6bp+/6bp+ 39 (86.7%) 18 (100%) NA (0.00–NA)
Recessive 6bp−/6bp− 6bp+/6bp− 30 (66.7%) 5 (27.8%) 1.00 0.005 71.4 75.7
6bp+/6bp+ 15 (33.3%) 13 (72.2%) 5.20 (1.56–17.32)
Over-dominant 6bp−/6bp 6bp+/6bp+ 21 (46.7%) 13 (72.2%) 1.00 0.062 75.9 80.2
6bp+/6bp− 24 (53.3%) 5 (27.8%) 0.34 (0.10–1.10)
Log-additive – – – 4.81 (1.56–14.77) 0.002 69.8 74.1
NA, not applicable; CI, confidence interval. Statistically significant associations are highlighted in bold. aLikelihood ratio test. bAkaike’s 
information criterion. cBayesian information criterion.
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Figure 2: Lack of response to chemotherapy with the number of 3RG 
alleles in the cohort of colorectal cancer patients.
p = 0.0033, Cochran-Armitage trend test.
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Discussion
The TYMS enzyme is the pharmacological target of the 
fluoropyrimidines and is mainly responsible for the cyto-
toxic effect. It is reasonable that variants in the regulatory 
regions of TYMS may affect the gene expression and are 
potential candidates for predicting clinical response and 
toxicity to fluoropyrimidines [22–24]. Our retrospective 
analysis of CRC patients shows a significant association 
between the number of 2R alleles of the VNTR variant in 
the region 5′UTR of the gene and serious global toxicity to 
fluoropyrimidines, a result confirmed by the prospective 
analysis of patients with colorectal tumors. Multivariate 
analysis of pooled data (prospective and retrospective) 
shows a recessive model for 2R allele and phenotype of 
severe toxicity to the fluoropyrimidines with a notorious 
OR value (5.21). Accordingly, the 2R/2R genotype has been 
linked to toxicity to fluoropyrimidines [25–28].
Some studies have related the 2R allele with lower 
gene expression; however, the relationship between the 
functional effect of two or more repetitions of this variant 
and the 5-FU effect is unclear [29–31].
We also found a significant association between 2R/2R 
genotype and ORR of colorectal cancer  patients to chemo-
therapy. This result was reported previously in patients 
with advanced gastrointestinal cancer treated with fluoro-
pyrimidines [32, 33]. The dual relationship between greater 
toxicity and better response with the genotype 2R/2R is dem-
onstrated in the clinical context [34–36]. The 2R/2R genotype 
may potentiate the drug cytotoxic effect by increasing the 
chemosensitivity of both, tumor and nontumor cells [37].
The variant G>C (rs2853542) showed a tendency towards 
poorer chemotherapeutic response with each copy of the G 
allele. Although the clinical effect of this variant has been 
less studied, our results confirm the report of Meulendijks 
et al. [33] regarding the negative effect of the G allele on the 
antineoplastic response. In vitro studies suggest that this 
allele modifies a putative sequence for the binding of the 
USF-1 transcription factor, decreasing the gene transcrip-
tional activity. This could be associated with increased 
tumor sensitivity to the fluoropyrimidines and better clini-
cal response [38, 39]. The absence of this allele in the geno-
types classified in the low expression category (i.e. 2R/2R, 
2R/3RC, 3RC/3RC) may explain the significant association 
between better clinical response and low expression geno-
types in this study [40]. This result was previously reported 
for esophageal cancer patients but not for CRC patients [41].
The 6bp+/6bp+ genotype of rs151264360  was asso-
ciated with good response to fluoropyrimidines, as 
described by Arrazubi et  al. [42] but contrasts with the 
report by Dotor et al. [43]. There are methodological dif-
ferences in the treatment administration schemes and 
sample origins that may explain the discrepancies. Our 
results also differ with two studies performed on Asian 
populations. An important difference is that 6bp−/6bp− 
genotype frequencies described in these studies are 
higher than those found in our cohort of patients [14, 44]. 
A comparison of VNTR genotype frequencies in similar 
studies from different populations shows similarities 
between Mexican and Caucasian populations from Italy, 
Hungary and Spain (2R/2R: 16%–24%, 2R/3R: 47%–49%, 
3R/3R: 29%–35%), but noticeable differences with East 
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Figure 3: Comparison between TYMS gene relative expression in tumor and nontumor colorectal tissues.
(A) Fold change in TYMS relative expression between tumor and nontumor adjacent colorectal tissues. p = 0.34, Wilcoxon signed-rank test. 
Results from three biological replicates. (B) TYMS relative expression by genotype of the VNTR variant in tumor (n = 11) and nontumor (n = 16) 
colorectal tissues. p < 0.05, Mann-Whitney U-test.
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Asian populations (2R/2R: 4%–5%, 2R/3R: 21%–29%, 
3R/3R: 67%–73%) [14, 15, 25, 45, 46]. The low frequencies 
of the 2R allele in the last geographical group may explain 
the absence of significant association between the VNTR 
and clinical response in these populations [47]. Similarity 
between frequencies found in this study with those from 
Caucasian populations may be explained by the Spaniard 
contributions to the admixed Mestizo genome in current 
north-eastern and western Mexicans (38% and 30%, 
respectively), as was previously established [48, 49].
The TYMS expression studies in our colorectal samples 
showed decreased gene expression in the 2R/2R tumor 
tissue samples. This observation agrees with reports indi-
cating better ORR to fluoropyrimidines in patients whose 
colorectal tumors have lower TYMS expression [50]. Our 
studies showed 100% genotypic correspondence between 
tumor and adjacent-tissue samples for the studied TYMS 
variants, suggesting that none of the tumors presented loss 
of heterozygosity as previously reported, particularly for the 
rs45445694 VNTR variant [51, 52]. Functional studies have 
reported in vitro and in vivo effects to the G>C (rs2853542) 
and VNTR variant in TYMS expression [38, 53, 54].
Regarding the 6 bp allele in the 3′UTR region of the 
gene, we did not find association between this allele and 
TYMS expression. This allele is related with decreased 
mRNA stability in vitro studies which results in lower 
enzyme expression but this finding requires in vivo con-
firmation [55].
Evidence presented here supports that rs45445694 
and rs151264360 are predictive biomarkers of response. 
However, the role of additional variants in noncoding 
regions of TYMS to chemotherapeutic response and toxic-
ity to fluoropyrimidines cannot be ruled out [56, 57].
Conclusions
The 2R/2R genotype of the VNTR (rs45445694) in the pro-
moter region of the TYMS gene is a predictive marker of 
clinical response and severe toxicity to the fluoropyrimi-
dines in CRC patients. It is possible that this genotype 
decreases the expression of the gene in the colorectal 
tumor tissue. The G variant in rs2853542 and the 6bp dele-
tion in rs151264360 (3′UTR region) are independent bio-
markers of therapeutic failure.
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